[HTML][HTML] ZEB1: catalyst of immune escape during tumor metastasis

J Lu, F Fei, C Wu, J Mei, J Xu, P Lu - Biomedicine & Pharmacotherapy, 2022 - Elsevier
The transcription factor zinc finger E-box binding homeobox 1 (ZEB1) is a critical inducer of
epithelial mesenchymal transformation (EMT) and plays a robust role in tumor metastasis. It …

Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer

MT Le, HT Nguyen, XH Nguyen, XH Do, BT Mai… - Heliyon, 2023 - cell.com
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80%–85% of total cases and leading to millions of deaths worldwide. Drug resistance is the …

Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy

ZR Dong, JB Cai, GM Shi, YF Yang, XY Huang… - Cancer Letters, 2023 - Elsevier
Evading immune destruction is an emerging hallmark of cancer and a potential key step in
tumorigenesis. Immune checkpoint blocker (ICB)-based combination therapies revolutionize …

Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness

C Ursino, C Mouric, L Gros, N Bonnefoy… - Frontiers in …, 2023 - frontiersin.org
Immune checkpoint blockade represents the latest revolution in cancer treatment by
substantially increasing patients' lifetime and quality of life in multiple neoplastic …

Epithelial− mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung …

H Jeong, J Koh, S Kim, SG Song, SH Lee… - British Journal of …, 2024 - nature.com
Background We investigated the role of tumor cell-intrinsic PD-L1 signaling in the epithelial−
mesenchymal transition (EMT) in non-small-cell lung cancer (NSCLC) and the role of EMT …

Immune checkpoint blockade therapy for breast cancer: lessons from epithelial–mesenchymal transition

I O'Connell, A Dongre - Molecular Diagnosis & Therapy, 2023 - Springer
Immune checkpoint blockade therapies have generated efficacious responses in certain
tumor types; however, the responses of breast carcinomas have been largely limited …

Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry

J Tímár, KV Honn, MJC Hendrix, G Marko-Varga… - Cancer and Metastasis …, 2023 - Springer
Cancer plasticity is now a recognized new hallmark of cancer which is due to disturbances
of cell differentiation programs. It is manifested not only in various forms like the best-known …

[HTML][HTML] Dual inhibition of KIF11 and BCL2L1 induces apoptosis in lung adenocarcinoma cells

Y Sakuma, S Hirai, T Sumi, T Niki… - … and Biophysical Research …, 2023 - Elsevier
EGFR-mutant lung adenocarcinoma (LUAD) mostly depends on EGFR for survival and
consequently responds well to EGFR inhibitors. However, resistance to the drugs develops …

LPS-induced monocarboxylate transporter-1 inhibition facilitates lactate accumulation triggering epithelial-mesenchymal transformation and pulmonary fibrosis

J Feng, H Zhong, S Mei, R Tang, Y Zhou, S Xing… - Cellular and Molecular …, 2024 - Springer
The epithelial-mesenchymal transformation (EMT) process of alveolar epithelial cells is
recognized as involved in the development of pulmonary fibrosis. Recent evidence has …

[HTML][HTML] Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the MIR141/MIR200C-ZEB1 …

J Vad-Nielsen, NH Staunstrup… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Epithelial-mesenchymal-transition (EMT) is an epigenetic-based mechanism
contributing to the acquired treatment resistance against receptor tyrosine kinase inhibitors …